Reproductive BioMedicine Online
Volume 20, Issue 5 , Pages 675-680 , May 2010

Serum inhibin A concentration in women with polycystic ovarian syndrome and the correlation to ethnicity, androgens and insulin resistance

  • Shimon Segal

      Affiliations

    • Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Room 5–18, Lincoln Medical Center, 234–149th Street, Bronx, NY 10451, USA
    • Repromedix Corporation, Woburn, MA, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Malvina Elmadjian

      Affiliations

    • Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Room 5–18, Lincoln Medical Center, 234–149th Street, Bronx, NY 10451, USA
    • ,
  • Takeko Takeshige

      Affiliations

    • Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Room 5–18, Lincoln Medical Center, 234–149th Street, Bronx, NY 10451, USA
    • ,
  • Steven Karp

      Affiliations

    • Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Room 5–18, Lincoln Medical Center, 234–149th Street, Bronx, NY 10451, USA
    • ,
  • Ray Mercado

      Affiliations

    • Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Room 5–18, Lincoln Medical Center, 234–149th Street, Bronx, NY 10451, USA
    • ,
  • Benjamin Rivnay

      Affiliations

    • Weill Medical College of Cornell University, NY, USA

Received 1 June 2009 ,Revised 19 November 2009 ,Accepted 15 January 2010.

References 

  1. Anderson RA, Groome NP, Baird DT. Inhibin A and Inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation. Clin. Endocrinol. 1998;48(5):577–584
  2. Andreani CL, Pierro E, Lanzone A, et al. Effect of gonadotropins, insulin and IGF I on granulosa luteal cells from polycystic ovaries. Mol. Cell. Endocrinol. 1994;106:91–97
  3. Azziz R, Woods RR, Key TJ, Knowchenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metabol. 2004;89:2745–2749
  4. Balen AH, Conway GS, Homburg R, Legro RS. Polycystic ovarian syndrome. A guide to clinical management. Taylor and Francis; 2000;p. 95
  5. Burger HG, Robertson DM, Cahir N, Mamers P, Jobling T, Groome S. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin. Endocrinol. (Oxf.). 1996;44:413–418
  6. Burger HG. Inhibin review. Reprod. Med. Rev. 1992;1:1–20
  7. Fujiwara T, Sidis Y, Welt C, Lambert-Messerlian G, Fox J, Taylor A. Dynamics of inhibin subunits and follistatin mRNA during development of normal and polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 2001;86:4206–4215
  8. Goodarzi MO, Quinones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil. Steril. 2005;84:766–769
  9. Groome NP, O’brien M. Immunoassays for inhibin and its subunits. J. Immunol. Methods. 1993;165:167–176
  10. Kauffman FP, Baker VM, Dimarino P, Gimpel T, Castracane VD. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women; a comparison of two distinct populations. American. J. Obstet. Gynecol. 2002;1362–1369
  11. Kumanov P, Nandipati KC, Tomova A, Robeva R, Agarwal A. Significance of inhibin in reproductive pathophysiology and current clinical applications. Reprod. Biomed. Online. 2005;10:786–796
  12. Lambert-Messerlian GM, Hall JA, Sluss PM, et al. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovaria syndrome using a specific two-site enzyme-linked immunosorbent assay. Clin. Endocrinol. Metab. 1994;79:45–50
  13. Legro RS, Myers E, Barnhart HX, Carson SA, Diamond MP, Carr BK, et al. The pregnancy in polycystic ovary syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil. Steril. 2006;86:914–933
  14. Lord J, Wilkin T. Polycystic ovary syndrome and fat distribution: the central issue?. Hum. Reprod. 2002;5:67–71
  15. Lockwood GM. The role of inhibin in polycystic ovarian syndrome. Hum. Fertil. (Camb.). 2000;3:86–92
  16. Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL. Mid- follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic diathermy: a possible mechanism regulating emergence of the dominant follicle. J. Clin. Endocrinol. Metab. 1998;83:1730–1736
  17. Magoffin DA, Jakimiuk AJ. Inhibin A, inhibin B, and activin A concentrations in follicular fluid from women with polycystic ovarian syndrome. Hum. Reprod. 1998;13:2693–2698
  18. Mason HD, Willis Beard RW, Winston RML, Margar R, Franks S. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J. Clin. Endocrinol. Metab. 1994;79:1355–1360
  19. Molskness TA, Woodruff TK, Hess DL, Dahl KD, Stouffer RL. Recombinant human inhibin-A administered early in the menstrual cycle alters concurrent pituitary and follicular, plus subsequent luteal, function in rhesus monkeys. J. Clin. Endocrinol. Metab. 1996;81:4002–4006
  20. Muttukrishna S, George L, Fowler PA, Groome NP, Knight PG. Measurement of serum concentrations of Inhibin-A (a-bA) during human pregnancy. Clin. Endocrinol. 1995;42:391–397
  21. Pigny P, Cortet-Rudelli C, Decanter C, et al. Serum levels of inhibins are differentially altered in patients with polycystic ovarian syndrome: effects of being overweight and relevance to hyperandrogenism. Fertil. Steril. 2000;73:972–977
  22. Rivier C, Corrigan A, Vale W. Effect of recombinant human inhibin on gonadotropin secretion by the male rat. Endocrinology. 1991;129:2155–2159
  23. Rivier C, Schwall R, Mason A, Burton L, Vaughan J, Vale W. Effect of recombinant inhibin on luteinizing hormone and follicle-stimulating hormone secretion in the rat. Endocrinology. 1991;128:1548–1554
  24. Rotterdam ESHRE/ASRM Sponsored PCOS Conesus Workshop Group, 2004. Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome 2004. Fertil. Steril. 81, 19–25.
  25. Segal S, Gor H, Correa N, Mercado R, Veenstra K, Rivnay B. Inhibin-A marker for diagnosis of ectopic and early abnormal pregnancies. Reprod. Biomed. Online. 2008;17:789–794
  26. Stouffer RL, Dahl KD, Hess DL, Woodruff TK, Mather JP, Molskness TA. Systemic and intraluteal infusion of inhibin A or activin A in rhesus monkeys during the luteal phase of the menstrual cycle. Biol. Reprod. 1994;50:888–895
  27. Tanabe K, Saijo A, Park JY, Kohriyama S, Sano Y, Nakamura Y, et al. The role of inhibin in women with polycystic ovarian syndrome. Horm. Res. 1990;33(Suppl. 2):10–17
  28. Tsigkou A, Luisi S, De Leo V, Patton L, Gambineri A, Reis FM, et al. High serum concentration of total inhibin in polycystic ovary syndrome. Fertil. Steril. 2008;90:1859–1863
  29. Welt CK, Taylor AE, Martin KA, Hall JA. Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone. J. Clin. Endocrinol. Metab. 2002;87:5559–5565
  30. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 1996;81:302–309
  31. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Frartks S. Pre mature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab. 1998;83:3984–3991

 Dr Segal graduated from the Faculty of General Medicine, Gr T Popa University of Medicine and Pharmacy, Iasi, Romania and completed his residency in Obstetrics and Gynecology at Hillel Yaffe Hospital, Israel and Mc Master University, Canada. He is currently in the Division of Reproductive Medicine Department of Obstetrics and Gynecology, Lincoln Medical Center, Weill Medical College of Cornell University, his special interest include reproductive medicine, infertility, IVF, polycystic ovarian syndrome, ovulation disorders, menopause and osteopororosis.

PII: S1472-6483(10)00062-3

doi: 10.1016/j.rbmo.2010.02.006

Reproductive BioMedicine Online
Volume 20, Issue 5 , Pages 675-680 , May 2010

Article Tools

* Image Usage & Resolution